Alliances
The approval of the combination marks a first for the U.S. market. The combination of AbbVie and Janssen’s Imbruvica with Roche’s Gazyva is the first chemotherapy-free, anti-CD20 combination to treat CLL and SLL patients who have not yet started therapy, AbbVie said this morning.
While Purdue battles numerous lawsuits over its alleged role in the opioid crisis, the Connecticut-based company has made inroads into developing non-opioid pain treatments.
Notable will donate the commercial rights to price, manufacture, and distribute ND-1000 for pediatric leukemia to Cures Within Reach.
Not only will a company use a significant amount of capital to make the acquisition, but there are longer-term issues, such as the merging of two company cultures, Franz said in an interview with CNBC.
BioNTech AG inked a deal with Munich, Germany’s MAB Discovery GmbH to acquire MAB’s operational antibody generation unit. No financial details were disclosed.
OCR and ImaBiotech have announced the launch of a new preclinical service for Biotech-Pharma-MedTech companies that allows drug efficacy and target exposure services at cellular level using Pets with naturally occurring tumors.
Janssen Pharmaceuticals and Apple have teamed up to determine if a new app for the Apple Watch, which has a built-in electrocardiogram can improve the health of more than 30 million people with atrial fibrillation (AFib), a condition that can lead to stroke and other potentially devastating complications.
Novartis and Oxford will use artificial intelligence and advanced analytics to identify early predictors of inflammatory diseases.
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
Aiming at a service which prevents dementia and enables a society of healthy longevity
PRESS RELEASES